[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638170":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":25,"responsibleParty":35,"collaborators":37,"id":43,"slug":25,"hasResults":44,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":44,"sex":50,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":25,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":68,"whyStopped":25,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":25},{"fullName":5,"class":6},"Anhui Provincial Hospital","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard Dose Group","ACTIVE_COMPARATOR","Participants receive standard-dose trimethoprim-sulfamethoxazole (TMP-SMX) 80\u002F400 mg once daily for 12 consecutive months for the prevention of Pneumocystis jirovecii pneumonia (PJP) after kidney transplantation.",[13],"Drug: Trimethoprim-Sulfamethoxazole (TMP-SMX)",{"label":15,"type":16,"description":17,"interventionNames":18},"Low Dose Group","EXPERIMENTAL","Participants receive trimethoprim-sulfamethoxazole (TMP-SMX) 40\u002F200 mg (half tablet) once daily for 12 consecutive months for the prevention of Pneumocystis jirovecii pneumonia (PJP) after kidney transplantation.",[13],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Trimethoprim-Sulfamethoxazole (TMP-SMX)","80\u002F400 mg orally once daily for 12 consecutive months for the prophylaxis",[9],null,{"type":21,"name":22,"description":27,"armGroupLabels":28,"otherNames":25},"40\u002F200 mg orally once daily for 12 consecutive months for the prophylaxis",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Xuqin jiang","CONTACT","+86-13675605989","xqjiang@ustc.edu.cn",{"type":36,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[38,41],{"name":39,"class":40},"The First Affiliated Hospital of Anhui Medical University","OTHER",{"name":42,"class":40},"The Second Hospital of Anhui Medical University","100638170",false,"NCT07619027","Low- vs Standard-Dose TMP-SMX for Prevention of Pneumocystis Pneumonia After Kidney Transplantation","A Prospective Randomized Controlled Study of Low-Dose Versus Standard-Dose Trimethoprim-Sulfamethoxazole for the Prevention of Pneumocystis Jirovecii Pneumonia After Kidney Transplantation","TMP-SMX PJP","Inclusion Criteria:\n\n-Age: Between 18 and 70 years old. Transplant Status: Recipients of a first-time kidney transplant. Renal Function: Serum creatinine levels have stabilized with a creatinine -----clearance (CrCl) \\> 30 mL\u002Fmin.\n\nConsent \\& Compliance: Voluntarily agree to participate in this study, are capable of cooperating with the investigators, and have signed the informed consent form.\n\nExclusion Criteria:\n\n-HIV Infection: Known HIV positive status. Drug Allergy: History of allergy or hypersensitivity to TMP-SMX (Trimethoprim-Sulfamethoxazole).\n\nPrior PJP: History of Pneumocystis jirovecii pneumonia (PJP) before transplantation.\n\nG6PD Deficiency: Glucose-6-phosphate dehydrogenase deficiency. Multi-organ Transplant: Recipients of multi-organ transplants. Active Infection: Presence of other severe concurrent infections. Immune System Disorders: Concomitant diseases affecting the immune system (e.g., malignancies\u002Ftumors, connective tissue diseases, hematological system diseases).\n\nPregnancy: Pregnant women. Anemia: Megaloblastic anemia. Non-compliance: Inability to adhere to regular follow-up schedules or poor compliance.","ALL","18 Years","70 Years",{"count":54,"type":55},1084,"ESTIMATED","INTERVENTIONAL",[58],"PHASE4","This study is a prospective randomized controlled trial designed to evaluate the efficacy and safety of low-dose versus standard-dose trimethoprim-sulfamethoxazole (TMP-SMX) for the prevention of Pneumocystis jirovecii pneumonia (PJP) in kidney transplant recipients.\n\nParticipants will be randomly assigned to receive either low-dose or standard-dose TMP-SMX for 12 months after kidney transplantation. The primary outcome is the incidence of PJP during the prophylaxis period. Secondary outcomes include adverse events related to TMP-SMX, dose reduction or discontinuation rates, incidence and timing of PJP after discontinuation, and other post-transplant complications.\n\nParticipants will be followed for a total of 24 months, including a 12-month prophylaxis period and an additional 12-month follow-up period after discontinuation. This study aims to provide evidence for optimizing prophylactic strategies against PJP in kidney transplant recipients.",[61,62],"Pneumocystis Jirovecii Pneumonia","Kidney Transplantation",[64,65,66,67],"PJP prophylaxis","Kidney transplant recipients","Trimethoprim-Sulfamethoxazole","Low-dose","NOT_YET_RECRUITING","2026-05-26",{"date":71,"type":72},"2026-06-01","ACTUAL",{"date":74,"type":55},"2026-06",{"date":76,"type":55},"2030-06",{"name":5,"class":6}]